1
|
Lopez-Tarruella S, Del Monte-Millán M, Roche-Molina M, Jerez Y, Echavarria Diaz-Guardamino I, Herrero López B, Gamez Casado S, Marquez-Rodas I, Alvarez E, Cebollero M, Massarrah T, Ocaña I, Arias A, García-Sáenz JÁ, Moreno Anton F, Olier Garate C, Moreno Muñoz D, Marrupe D, Lara Álvarez MÁ, Enrech S, Bueno Muiño C, Martín M. Correlation between breast cancer subtypes determined by immunohistochemistry and n-COUNTER PAM50 assay: a real-world study. Breast Cancer Res Treat 2024; 203:163-172. [PMID: 37773555 PMCID: PMC10771357 DOI: 10.1007/s10549-023-07094-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2023] [Accepted: 08/13/2023] [Indexed: 10/01/2023]
Abstract
PURPOSE Molecular subtyping based on gene expression profiling (i.e., PAM50 assay) aids in determining the prognosis and treatment of breast cancer (BC), particularly in hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative tumors, where luminal A and B subtypes have different prognoses and treatments. Several surrogate classifications have been proposed for distinguishing between the luminal A and B subtypes. This study determines the accuracy of local immunohistochemistry (IHC) techniques for classifying HR-positive/HER2-negative (HR+/HER2-) tumors according to intrinsic subtypes using the nCOUNTER PAM50 assay as reference and the HR status definition according the ASCO/CAP recommendations. METHODS Molecular subtypes resulting from nCOUNTER PAM50 performed in our laboratory between 2014 and 2020 were correlated with three different proxy surrogates proposed in the literature based on ER, PR, HER2, and Ki67 expression with different cut-off values. Concordance was measured using the level of agreement and kappa statistics. RESULTS From 1049 samples with the nCOUNTER test, 679 and 350 were luminal A and B subtypes, respectively. Only a poor-to-fair correlation was observed between the three proxy surrogates and real genomic subtypes as determined by nCOUNTER PAM50. Moreover, 5-11% and 18-36% of the nCOUNTER PAM50 luminal B and A tumors were classified as luminal A and B, respectively, by these surrogates. CONCLUSION The concordance between luminal subtypes determined by three different IHC-based classifiers and the nCOUNTER PAM50 assay was suboptimal. Thus, a significant proportion of luminal A and B tumors as determined by the surrogate classifiers could be undertreated or over-treated.
Collapse
Affiliation(s)
- Sara Lopez-Tarruella
- Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañon (IiSGM), CIBERONC, Geicam, Universidad Complutense, 28007, Madrid, Spain
| | - María Del Monte-Millán
- Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), CiberOnc, Madrid, Spain
| | - Marta Roche-Molina
- Medical Oncology Department, Hospital General Universitario Gregorio Marañón Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain
| | - Yolanda Jerez
- Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), CiberOnc, Madrid, Spain
| | - Isabel Echavarria Diaz-Guardamino
- Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), CiberOnc, Madrid, Spain
| | - Blanca Herrero López
- Medical Oncology Department, Hospital General Universitario Gregorio Marañón Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain
| | - Salvador Gamez Casado
- Medical Oncology Department, Hospital General Universitario Gregorio Marañón Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain
| | - Iván Marquez-Rodas
- Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), CiberOnc, Madrid, Spain
| | - Enrique Alvarez
- Medical Oncology Department, Hospital General Universitario Gregorio Marañón Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain
| | - María Cebollero
- Pathology Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - Tatiana Massarrah
- Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), CiberOnc, Madrid, Spain
| | - Inmaculada Ocaña
- Medical Oncology Department, Hospital General Universitario Gregorio Marañón Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain
| | - Ainhoa Arias
- Medical Oncology Department, Hospital General Universitario Gregorio Marañón Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain
| | - José Ángel García-Sáenz
- Medical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria San Carlos (IdISSC), CIBERONC, Madrid, Spain
| | - Fernando Moreno Anton
- Medical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria San Carlos (IdISSC), CIBERONC, Madrid, Spain
| | - Clara Olier Garate
- Medical Oncology Department, Hospital Universitario Fundación Alcorcón, Alcorcon, Spain
| | - Diana Moreno Muñoz
- Medical Oncology Department, Hospital Universitario Fundación Alcorcón, Alcorcon, Spain
| | - David Marrupe
- Department of Oncologia, Hospital Universitario de Móstoles, Mostoles, Spain
| | - Miguel Ángel Lara Álvarez
- Medical Oncology Department, Hospital Universitario Infanta Leonor, Universidad Complutense, Madrid, Spain
| | - Santos Enrech
- Medical Oncology Department, Hospital Universitario de Getafe, Madrid, Spain
| | - Coralia Bueno Muiño
- Medical Oncology Department, Hospital Infanta Cristina (Parla), Fundación de Investigación Biomédica del H.U. Puerta de Hierro, Majadahonda, 28009, Madrid, Spain
| | - Miguel Martín
- Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañon (IiSGM), CIBERONC, Geicam, Universidad Complutense, 28007, Madrid, Spain.
| |
Collapse
|
2
|
García-Quintáns N, Sacristán S, Márquez-López C, Sánchez-Ramos C, Martinez-de-Benito F, Siniscalco D, González-Guerra A, Camafeita E, Roche-Molina M, Lytvyn M, Morera D, Guillen MI, Sanguino MA, Sanz-Rosa D, Martín-Pérez D, Garcia R, Bernal JA. MYH10 activation rescues contractile defects in arrhythmogenic cardiomyopathy (ACM). Nat Commun 2023; 14:6461. [PMID: 37833253 PMCID: PMC10575922 DOI: 10.1038/s41467-023-41981-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2023] [Accepted: 09/26/2023] [Indexed: 10/15/2023] Open
Abstract
The most prevalent genetic form of inherited arrhythmogenic cardiomyopathy (ACM) is caused by mutations in desmosomal plakophilin-2 (PKP2). By studying pathogenic deletion mutations in the desmosomal protein PKP2, here we identify a general mechanism by which PKP2 delocalization restricts actomyosin network organization and cardiac sarcomeric contraction in this untreatable disease. Computational modeling of PKP2 variants reveals that the carboxy-terminal (CT) domain is required for N-terminal domain stabilization, which determines PKP2 cortical localization and function. In mutant PKP2 cells the expression of the interacting protein MYH10 rescues actomyosin disorganization. Conversely, dominant-negative MYH10 mutant expression mimics the pathogenic CT-deletion PKP2 mutant causing actin network abnormalities and right ventricle systolic dysfunction. A chemical activator of non-muscle myosins, 4-hydroxyacetophenone (4-HAP), also restores normal contractility. Our findings demonstrate that activation of MYH10 corrects the deleterious effect of PKP2 mutant over systolic cardiac contraction, with potential implications for ACM therapy.
Collapse
Affiliation(s)
| | - Silvia Sacristán
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain
| | | | | | - Fernando Martinez-de-Benito
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain
- CIBER de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain
| | - David Siniscalco
- Materials Science Factory, Instituto de Ciencia de Materiales de Madrid (ICMM), CSIC, Madrid, Spain
| | | | - Emilio Camafeita
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain
- CIBER de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain
| | - Marta Roche-Molina
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain
| | - Mariya Lytvyn
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain
| | - David Morera
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain
| | - María I Guillen
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain
| | - María A Sanguino
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain
| | - David Sanz-Rosa
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain
- CIBER de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain
- Universidad Europea, Madrid, Spain
| | | | - Ricardo Garcia
- Materials Science Factory, Instituto de Ciencia de Materiales de Madrid (ICMM), CSIC, Madrid, Spain
| | - Juan A Bernal
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
- CIBER de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.
| |
Collapse
|
3
|
Villacampa G, Tung NM, Pernas S, Paré L, Bueno-Muiño C, Echavarría I, López-Tarruella S, Roche-Molina M, Del Monte-Millán M, Marín-Aguilera M, Brasó-Maristany F, Waks AG, Pascual T, Martínez-Sáez O, Vivancos A, Conte PF, Guarneri V, Vittoria Dieci M, Griguolo G, Cortés J, Llombart-Cussac A, Muñoz M, Vidal M, Adamo B, Wolff AC, DeMichele A, Villagrasa P, Parker JS, Perou CM, Fernandez-Martinez A, Carey LA, Mittendorf EA, Martín M, Prat A, Tolaney SM. Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer. Ann Oncol 2023; 34:783-795. [PMID: 37302750 PMCID: PMC10735273 DOI: 10.1016/j.annonc.2023.05.012] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2023] [Revised: 05/24/2023] [Accepted: 05/25/2023] [Indexed: 06/13/2023] Open
Abstract
BACKGROUND The HER2DX genomic test predicts pathological complete response (pCR) and survival outcome in early-stage HER2-positive (HER2+) breast cancer. Here, we evaluated the association of HER2DX scores with (i) pCR according to hormone receptor status and various treatment regimens, and (ii) survival outcome according to pCR status. MATERIALS AND METHODS Seven neoadjuvant cohorts with HER2DX and clinical individual patient data were evaluated (DAPHNe, GOM-HGUGM-2018-05, CALGB-40601, ISPY-2, BiOnHER, NEOHER and PAMELA). All patients were treated with neoadjuvant trastuzumab (n = 765) in combination with pertuzumab (n = 328), lapatinib (n = 187) or without a second anti-HER2 drug (n = 250). Event-free survival (EFS) and overall survival (OS) outcomes were available in a combined series of 268 patients (i.e. NEOHER and PAMELA) with a pCR (n = 118) and without a pCR (n = 150). Cox models were adjusted to evaluate whether HER2DX can identify patients with low or high risk beyond pCR status. RESULTS HER2DX pCR score was significantly associated with pCR in all patients [odds ratio (OR) per 10-unit increase = 1.59, 95% confidence interval 1.43-1.77; area under the ROC curve = 0.75], with or without dual HER2 blockade. A statistically significant increase in pCR rate due to dual HER2 blockade over trastuzumab-only was observed in HER2DX pCR-high tumors treated with chemotherapy (OR = 2.36 (1.09-5.42). A statistically significant increase in pCR rate due to multi-agent chemotherapy over a single taxane was observed in HER2DX pCR-medium tumors treated with dual HER2 blockade (OR = 3.11, 1.54-6.49). The pCR rates in HER2DX pCR-low tumors were ≤30.0% regardless of treatment administered. After adjusting by pCR status, patients identified as HER2DX low-risk had better EFS (P < 0.001) and OS (P = 0.006) compared with patients with HER2DX high-risk. CONCLUSIONS HER2DX pCR score and risk score might help identify ideal candidates to receive neoadjuvant dual HER2 blockade in combination with a single taxane in early-stage HER2+ breast cancer.
Collapse
Affiliation(s)
- G Villacampa
- SOLTI Breast Cancer Research Group, Barcelona; Oncology Data Science, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | | | - S Pernas
- Medical Oncology Department, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona
| | - L Paré
- Reveal Genomics, Barcelona
| | - C Bueno-Muiño
- Medical Oncology Department, Hospital Infanta Cristina (Parla), Fundación de Investigación Biomédica del H.U. Puerta de Hierro, Majadahonda, Madrid
| | - I Echavarría
- Department of Medical Oncology, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, CiberOnc, Madrid
| | - S López-Tarruella
- Department of Medical Oncology, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, CiberOnc, Madrid
| | - M Roche-Molina
- Department of Medical Oncology, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, CiberOnc, Madrid
| | - M Del Monte-Millán
- Department of Medical Oncology, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, CiberOnc, Madrid
| | | | - F Brasó-Maristany
- Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona; Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain
| | - A G Waks
- Medical Oncology, Dana-Farber Cancer Institute, Boston; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston; Harvard Medical School, Boston, USA
| | - T Pascual
- SOLTI Breast Cancer Research Group, Barcelona; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona; Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain
| | - O Martínez-Sáez
- Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona; Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain
| | - A Vivancos
- Cancer Genomics Group, VHIO, Barcelona, Spain
| | - P F Conte
- Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova; Istituto Oncologico Veneto, IRCCS, Padova, Italy
| | - V Guarneri
- Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova; Istituto Oncologico Veneto, IRCCS, Padova, Italy
| | - M Vittoria Dieci
- Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova; Istituto Oncologico Veneto, IRCCS, Padova, Italy
| | - G Griguolo
- Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova; Istituto Oncologico Veneto, IRCCS, Padova, Italy
| | - J Cortés
- International Breast Cancer Center, Pangaea Oncology, Quirónsalud Group, Barcelona
| | - A Llombart-Cussac
- Arnau de Vilanova Hospital, Universidad Católica de Valencia, Valencia, Spain
| | - M Muñoz
- Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona; Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain
| | - M Vidal
- Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona; Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain
| | - B Adamo
- Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona; Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain
| | - A C Wolff
- Department of Oncology, Johns Hopkins University School of Medicine, Baltimore
| | - A DeMichele
- Department of Oncology, University of Pennsylvania, Philadelphia
| | | | - J S Parker
- Lineberger Comprehensive Cancer Center, Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill
| | - C M Perou
- Lineberger Comprehensive Cancer Center, Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill
| | - A Fernandez-Martinez
- Lineberger Comprehensive Cancer Center, Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill
| | - L A Carey
- Lineberger Comprehensive Cancer Center, Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill
| | - E A Mittendorf
- Medical Oncology, Dana-Farber Cancer Institute, Boston; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston; Harvard Medical School, Boston, USA; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, USA
| | - M Martín
- Department of Medical Oncology, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, CiberOnc, Madrid
| | - A Prat
- Reveal Genomics, Barcelona; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona; Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain; Institute of Oncology (IOB)-Quirón, Barcelona, Spain.
| | - S M Tolaney
- Medical Oncology, Dana-Farber Cancer Institute, Boston; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston; Institute of Oncology (IOB)-Quirón, Barcelona, Spain.
| |
Collapse
|
4
|
Bueno-Muiño C, Echavarría I, López-Tarruella S, Roche-Molina M, del Monte-Millán M, Massarrah T, Jerez Y, Ayala de la Peña F, García-Sáenz JÁ, Moreno F, Rodríguez-Lescure Á, Malón-Giménez D, Ballesteros García AI, Marín-Aguilera M, Galván P, Brasó-Maristany F, Waks AG, Tolaney SM, Mittendorf EA, Vivancos A, Villagrasa P, Parker JS, Perou CM, Paré L, Villacampa G, Prat A, Martín M. Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab. JAMA Oncol 2023; 9:841-846. [PMID: 37103916 PMCID: PMC10141274 DOI: 10.1001/jamaoncol.2023.0187] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2022] [Accepted: 12/22/2022] [Indexed: 04/28/2023]
Abstract
Importance Biomarkers to guide the use of pertuzumab in the treatment of early-stage ERBB2 (formerly HER2)-positive breast cancer beyond simple ERBB2 status are needed. Objective To determine if use of the HER2DX genomic assay (Reveal Genomics) in pretreatment baseline tissue samples of patients with ERBB2-positive breast cancer is associated with response to neoadjuvant trastuzumab-based chemotherapy with or without pertuzumab. Design, Setting, and Participants This is a retrospective diagnostic/prognostic analysis of a multicenter academic observational study in Spain performed during 2018 to 2022 (GOM-HGUGM-2018-05). In addition, a combined analysis with 2 previously reported trials of neoadjuvant cohorts with results from the assay (DAPHNe and I-SPY2) was performed. All patients had stage I to III ERBB2-positive breast cancer, signed informed consent, and had available formalin-fixed paraffin-embedded tumor specimens obtained prior to starting therapy. Exposures Patients received intravenous trastuzumab, 8 mg/kg, loading dose, followed by 6 mg/kg every 3 weeks in combination with intravenous docetaxel, 75 mg/m2, every 3 weeks and intravenous carboplatin area under the curve of 6 every 3 weeks for 6 cycles, or this regimen plus intravenous pertuzumab, 840 mg, loading dose, followed by an intravenous 420-mg dose every 3 weeks for 6 cycles. Main Outcome and Measures Association of baseline assay-reported pathologic complete response (pCR) score with pCR in the breast and axilla, as well as association of baseline assay-reported pCR score with response to pertuzumab. Results The assay was evaluated in 155 patients with ERBB2-positive breast cancer (mean [range] age, 50.3 [26-78] years). Clinical T1 to T2 and node-positive disease was present in 113 (72.9%) and 99 (63.9%) patients, respectively, and 105 (67.7%) tumors were hormone receptor positive. The overall pCR rate was 57.4% (95% CI, 49.2%-65.2%). The proportion of patients in the assay-reported pCR-low, pCR-medium, and pCR-high groups was 53 (34.2%), 54 (34.8%), and 48 (31.0%), respectively. In the multivariable analysis, the assay-reported pCR score (as a continuous variable from 0-100) showed a statistically significant association with pCR (odds ratio [OR] per 10-unit increase, 1.43; 95% CI, 1.22-1.70; P < .001). The pCR rates in the assay-reported pCR-high and pCR-low groups were 75.0% and 28.3%, respectively (OR, 7.85; 95% CI, 2.67-24.91; P < .001). In the combined analysis (n = 282), an increase in pCR rate due to pertuzumab was found in the assay-reported pCR-high tumors (OR, 5.36; 95% CI, 1.89-15.20; P < .001) but not in the assay-reported pCR-low tumors (OR, 0.86; 95% CI, 0.30-2.46; P = .77). A statistically significant interaction between the assay-reported pCR score and the effect of pertuzumab in pCR was observed. Conclusions and Relevance This diagnostic/prognostic study demonstrated that the genomic assay predicted pCR following neoadjuvant trastuzumab-based chemotherapy with or without pertuzumab. This assay could guide therapeutic decisions regarding the use of neoadjuvant pertuzumab.
Collapse
Affiliation(s)
- Coralia Bueno-Muiño
- Medical Oncology Department, Hospital Infanta Cristina (Parla), Fundación de Investigación Biomédica del H.U. Puerta de Hierro, Majadahonda, Madrid, Spain
| | - Isabel Echavarría
- Department of Medical Oncology, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, Madrid, Spain
| | - Sara López-Tarruella
- Department of Medical Oncology, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, Geicam, Universidad Complutense, Madrid, Spain
| | - Marta Roche-Molina
- Department of Medical Oncology, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain
| | - María del Monte-Millán
- Department of Medical Oncology, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, Madrid, Spain
| | - Tatiana Massarrah
- Department of Medical Oncology, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, Madrid, Spain
| | - Yolanda Jerez
- Department of Medical Oncology, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, Madrid, Spain
| | | | - José Ángel García-Sáenz
- Medical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria San Carlos, CIBERONC, Madrid, Spain
| | - Fernando Moreno
- Medical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria San Carlos, CIBERONC, Madrid, Spain
| | | | | | | | | | - Patricia Galván
- Translational Genomics and Targeted Therapies in Solid Tumors, Department of Medical Oncology, Hospital Clínic of Barcelona, Barcelona, Spain
| | - Fara Brasó-Maristany
- Translational Genomics and Targeted Therapies in Solid Tumors, Department of Medical Oncology, Hospital Clínic of Barcelona, Barcelona, Spain
| | - Adrienne G. Waks
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
- Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts
- Harvard Medical School, Boston, Massachusetts
| | - Sara M. Tolaney
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
- Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts
- Harvard Medical School, Boston, Massachusetts
| | - Elizabeth A. Mittendorf
- Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts
- Harvard Medical School, Boston, Massachusetts
- Division of Breast Surgery, Department of Surgery, Brigham and Women’s Hospital, Boston, Massachusetts
| | - Ana Vivancos
- Cancer Genomics Group, Vall d’Hebron Institute of Oncology, Barcelona, Spain
| | | | - Joel. S. Parker
- Department of Genetics, Lineberger Comprehensive Cancer Center, School of Medicine, University of North Carolina at Chapel Hill
| | - Charles M. Perou
- Department of Genetics, Lineberger Comprehensive Cancer Center, School of Medicine, University of North Carolina at Chapel Hill
| | | | | | - Aleix Prat
- Reveal Genomics, Barcelona, Spain
- Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain
- Department of Medical Oncology, Hospital Clinic of Barcelona, Spain
- Institute of Oncology-Quirón, Barcelona, Spain
| | - Miguel Martín
- Department of Medical Oncology, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, Geicam, Universidad Complutense, Madrid, Spain
| |
Collapse
|
5
|
Martín Lozano R, Roche-Molina M, Alvarez E, Del Monte-Millan M, Jerez Gilarranz Y, Moreno Anton F, García Saenz J, Echavarria Diaz-Guardamino I, Massarrah T, Cebollero M, Ballesteros Garcia A, Bohn Sarmiento U, Gomez Moreno H, Fuentes H, Herrero Lopez B, Gamez Casado S, Bueno Muiño C, Bueno O, Lopez-Tarruella Cobo S, Martin Jimenez M. 216P Relationship between regulatory T lymphocytes (Treg): Related genes and pathological response to neoadjuvant docetaxel-carboplatin in early-stage triple-negative breast cancer (TNBC). Immuno-Oncology and Technology 2022. [DOI: 10.1016/j.iotech.2022.100327] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
6
|
Echavarria Diaz-Guardamino I, Lopez-Tarruella Cobo S, Del Monte-Millan M, Alvarez E, Jerez Y, Moreno Anton F, García Saenz J, Massarrah T, Ocaña I, Cebollero M, Ballesteros Garcia A, Bohn Sarmiento U, Gomez H, Fuentes H, Herrero Lopez B, Gamez Casado S, Bueno O, Jiménez-Santos M, Roche-Molina M, Martin Jimenez M. 141MO Pathological response and early survival data according to TNBCtype4 classifier in operable triple-negative breast cancer (TNBC) treated with neoadjuvant carboplatin and docetaxel. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.176] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
7
|
Martín M, Del Monte-Millán M, Jerez Y, Echavarria Diaz-Guardamino I, Herrero Lopez B, Gamez Casado S, Roche-Molina M, Marquez-Rodas I, Cebollero M, Alvarez E, Massarrah T, Ocaña I, Arias A, García Saenz J, Moreno Anton F, Olier Garate C, Moreno Muñoz D, Marrupe Gonzalez D, Merina T, Lopez-Tarruella Cobo S. 85P Correlation between nCOUNTER PAM-50 assay and three IHC-based surrogate intrinsic breast cancer subtype classifiers: A real-world study. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.03.100] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
8
|
Macias A, González-Guerra A, Moreno-Manuel AI, Cruz FM, García-Quintáns N, Gutiérrez LK, Roche-Molina M, Bermúdez-Jiménez FJ, Andrés V, Vera-Pedrosa ML, Martínez-Carrascoso I, Bernal JA, Jalife J. Abstract P356: Dual Dysfunction Of Kir2.1 Underlies Conduction And Excitation-contraction Coupling Defects Promoting Arrhythmias In A Mouse Model Of Andersen-tawil Syndrome Type 1. Circ Res 2021. [DOI: 10.1161/res.129.suppl_1.p356] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background:
Andersen-Tawil syndrome type 1 (ATS1), caused by trafficking deficient mutations in the gene
KCNJ2
coding the inward rectifier K
+
channel Kir2.1, is associated with life-threatening arrhythmias, which in some patients resemble catecholaminergic polymorphic ventricular tachycardia (CPVT), but the mechanisms are poorly understood. We tested the hypothesis that dysfunction of two different populations of mutant Kir2.1 channels, one at the sarcolemma, and the other at the sarcoplasmic reticulum (SR) membrane, directly alters conduction and intracellular calcium dynamics, respectively, to promote the ATS1 phenotype and arrhythmias that resemble CPVT.
Methods:
We generated a new mouse model of ATS1 by a single i.v. injection of cardiac specific adeno-associated viral (AAV) transduction with Kir2.1
Δ314-315
.
In-vivo
and cellular, structural and functional analyses of the model were carried out by electrocardiogram (ECG), magnetic resonance imaging (MRI), intracardiac stimulation, patch-clamping, membrane fractionation, western blot, immunolocalization and live calcium imaging.
Results:
Our mouse model carrying mutant Kir2.1
Δ314-315
recapitulated the ATS1 phenotype without modifying ventricular function. On ECG, Kir2.1
Δ314-315
mice had prolonged PR, QRS and QT intervals and occasional U waves. They showed significantly slower conduction velocities than wildtype mice in response to flecaidine-induced Na
+
-channel blockade, additional QT prolongation in response to isoproterenol, and increased vulnerability to cardiac fibrillation. Cardiomyocytes from Kir2.1
Δ314-315
mice had significantly reduced inward rectifier K
+
and Na
+
inward currents, depolarized resting membrane potential and prolonged action potential duration. Immunolocalization in wildtype cardiomyocytes and skeletal muscle cells revealed a novel SR microdomain of functional Kir2.1 channels contributing to intracellular Ca
2+
homeostasis. Kir2.1
Δ314-315
cardiomyocytes showed defects in SR Kir2.1 localization and function, which contributed to abnormal spontaneous Ca
2+
release events.
Conclusions:
Cardiac-specific AAV transduction with Kir2.1
Δ314-315
in mice recapitulates the ATS1 phenotype by disrupting localization and function of Kir2.1 channels at the SR, and the Kir2.1-Na
V
1.5 channelosome at the sarcolemma. These results reveal a novel dual mechanism of arrhythmogenesis in ATS1 involving defects in Kir2.1 channel trafficking and function at two different microdomains. They also provide the first demonstration at the molecular level of the mechanism underlying the overlap between ATS1 and CPVT associated with defects in intracellular calcium homeostasis.
Collapse
|
9
|
Gonzalez-Guerra A, Roche-Molina M, García-Quintáns N, Sánchez-Ramos C, Martín-Pérez D, Lytvyn M, de Nicolás-Hernández J, Rivera-Torres J, Arroyo DF, Sanz-Rosa D, Bernal JA. Sustained Elevated Blood Pressure Accelerates Atherosclerosis Development in a Preclinical Model of Disease. Int J Mol Sci 2021; 22:8448. [PMID: 34445154 PMCID: PMC8395088 DOI: 10.3390/ijms22168448] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2021] [Revised: 07/29/2021] [Accepted: 08/03/2021] [Indexed: 11/20/2022] Open
Abstract
The continuous relationship between blood pressure (BP) and cardiovascular events makes the distinction between elevated BP and hypertension based on arbitrary cut-off values for BP. Even mild BP elevations manifesting as high-normal BP have been associated with cardiovascular risk. We hypothesize that persistent elevated BP increases atherosclerotic plaque development. To evaluate this causal link, we developed a new mouse model of elevated BP based on adeno-associated virus (AAV) gene transfer. We constructed AAV vectors to support transfer of the hRenin and hAngiotensinogen genes. A single injection of AAV-Ren/Ang (1011 total viral particles) induced sustained systolic BP increase (130 ± 20 mmHg, vs. 110 ± 15 mmHg in controls; p = 0.05). In ApoE-/- mice, AAV-induced mild BP elevation caused larger atherosclerotic lesions evaluated by histology (10-fold increase vs. normotensive controls). In this preclinical model, atheroma plaques development was attenuated by BP control with a calcium channel blocker, indicating that a small increase in BP within a physiological range has a substantial impact on plaque development in a preclinical model of atherosclerosis. These data support that non-optimal BP represents a risk for atherosclerosis development. Earlier intervention in elevated BP may prevent or delay morbidity and mortality associated with atherosclerosis.
Collapse
Affiliation(s)
- Andrés Gonzalez-Guerra
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), 28029 Madrid, Spain; (A.G.-G.); (M.R.-M.); (N.G.-Q.); (C.S.-R.); (D.M.-P.); (M.L.); (J.d.N.-H.); (J.R.-T.); (D.F.A.); (D.S.-R.)
| | - Marta Roche-Molina
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), 28029 Madrid, Spain; (A.G.-G.); (M.R.-M.); (N.G.-Q.); (C.S.-R.); (D.M.-P.); (M.L.); (J.d.N.-H.); (J.R.-T.); (D.F.A.); (D.S.-R.)
| | - Nieves García-Quintáns
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), 28029 Madrid, Spain; (A.G.-G.); (M.R.-M.); (N.G.-Q.); (C.S.-R.); (D.M.-P.); (M.L.); (J.d.N.-H.); (J.R.-T.); (D.F.A.); (D.S.-R.)
| | - Cristina Sánchez-Ramos
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), 28029 Madrid, Spain; (A.G.-G.); (M.R.-M.); (N.G.-Q.); (C.S.-R.); (D.M.-P.); (M.L.); (J.d.N.-H.); (J.R.-T.); (D.F.A.); (D.S.-R.)
| | - Daniel Martín-Pérez
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), 28029 Madrid, Spain; (A.G.-G.); (M.R.-M.); (N.G.-Q.); (C.S.-R.); (D.M.-P.); (M.L.); (J.d.N.-H.); (J.R.-T.); (D.F.A.); (D.S.-R.)
| | - Mariya Lytvyn
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), 28029 Madrid, Spain; (A.G.-G.); (M.R.-M.); (N.G.-Q.); (C.S.-R.); (D.M.-P.); (M.L.); (J.d.N.-H.); (J.R.-T.); (D.F.A.); (D.S.-R.)
| | - Javier de Nicolás-Hernández
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), 28029 Madrid, Spain; (A.G.-G.); (M.R.-M.); (N.G.-Q.); (C.S.-R.); (D.M.-P.); (M.L.); (J.d.N.-H.); (J.R.-T.); (D.F.A.); (D.S.-R.)
| | - José Rivera-Torres
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), 28029 Madrid, Spain; (A.G.-G.); (M.R.-M.); (N.G.-Q.); (C.S.-R.); (D.M.-P.); (M.L.); (J.d.N.-H.); (J.R.-T.); (D.F.A.); (D.S.-R.)
- Facultad CC Biomédicas, Universidad Europea, 28670 Madrid, Spain
| | - Diego F. Arroyo
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), 28029 Madrid, Spain; (A.G.-G.); (M.R.-M.); (N.G.-Q.); (C.S.-R.); (D.M.-P.); (M.L.); (J.d.N.-H.); (J.R.-T.); (D.F.A.); (D.S.-R.)
- Servicio de Cardiología, Hospital Universitario Virgen Macarena, 41009 Sevilla, Spain
| | - David Sanz-Rosa
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), 28029 Madrid, Spain; (A.G.-G.); (M.R.-M.); (N.G.-Q.); (C.S.-R.); (D.M.-P.); (M.L.); (J.d.N.-H.); (J.R.-T.); (D.F.A.); (D.S.-R.)
- Facultad CC Biomédicas, Universidad Europea, 28670 Madrid, Spain
- CIBERCV, 28029 Madrid, Spain
| | - Juan A. Bernal
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), 28029 Madrid, Spain; (A.G.-G.); (M.R.-M.); (N.G.-Q.); (C.S.-R.); (D.M.-P.); (M.L.); (J.d.N.-H.); (J.R.-T.); (D.F.A.); (D.S.-R.)
- CIBERCV, 28029 Madrid, Spain
| |
Collapse
|
10
|
Macias A, González-Guerra A, Moreno-Manuel AI, Cruz FM, García-Quintáns N, Gutiérrez LK, Roche-Molina M, Bermúdez-Jiménez F, Vera-Pedrosa ML, Martínez-Carrascoso I, Bernal JA, Jalife J. B-AB18-02 KIR2.1 CHANNELS IN A NOVEL SARCOPLASMIC RETICULUM MICRODOMAIN CONTROL INTRACELLULAR CA2+ DYNAMICS. Heart Rhythm 2021. [DOI: 10.1016/j.hrthm.2021.06.103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
11
|
Nicolás-Ávila JA, Lechuga-Vieco AV, Esteban-Martínez L, Sánchez-Díaz M, Díaz-García E, Santiago DJ, Rubio-Ponce A, Li JL, Balachander A, Quintana JA, Martínez-de-Mena R, Castejón-Vega B, Pun-García A, Través PG, Bonzón-Kulichenko E, García-Marqués F, Cussó L, A-González N, González-Guerra A, Roche-Molina M, Martin-Salamanca S, Crainiciuc G, Guzmán G, Larrazabal J, Herrero-Galán E, Alegre-Cebollada J, Lemke G, Rothlin CV, Jimenez-Borreguero LJ, Reyes G, Castrillo A, Desco M, Muñoz-Cánoves P, Ibáñez B, Torres M, Ng LG, Priori SG, Bueno H, Vázquez J, Cordero MD, Bernal JA, Enríquez JA, Hidalgo A. A Network of Macrophages Supports Mitochondrial Homeostasis in the Heart. Cell 2020; 183:94-109.e23. [PMID: 32937105 DOI: 10.1016/j.cell.2020.08.031] [Citation(s) in RCA: 318] [Impact Index Per Article: 79.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2019] [Revised: 06/22/2020] [Accepted: 08/17/2020] [Indexed: 12/18/2022]
Abstract
Cardiomyocytes are subjected to the intense mechanical stress and metabolic demands of the beating heart. It is unclear whether these cells, which are long-lived and rarely renew, manage to preserve homeostasis on their own. While analyzing macrophages lodged within the healthy myocardium, we discovered that they actively took up material, including mitochondria, derived from cardiomyocytes. Cardiomyocytes ejected dysfunctional mitochondria and other cargo in dedicated membranous particles reminiscent of neural exophers, through a process driven by the cardiomyocyte's autophagy machinery that was enhanced during cardiac stress. Depletion of cardiac macrophages or deficiency in the phagocytic receptor Mertk resulted in defective elimination of mitochondria from the myocardial tissue, activation of the inflammasome, impaired autophagy, accumulation of anomalous mitochondria in cardiomyocytes, metabolic alterations, and ventricular dysfunction. Thus, we identify an immune-parenchymal pair in the murine heart that enables transfer of unfit material to preserve metabolic stability and organ function. VIDEO ABSTRACT.
Collapse
Affiliation(s)
- José A Nicolás-Ávila
- Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid 28029, Spain
| | - Ana V Lechuga-Vieco
- Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid 28029, Spain; CIBER de enfermedades respiratorias (CIBERES), Madrid 28029, Spain
| | | | - María Sánchez-Díaz
- Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid 28029, Spain
| | - Elena Díaz-García
- Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid 28029, Spain
| | - Demetrio J Santiago
- Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid 28029, Spain
| | - Andrea Rubio-Ponce
- Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid 28029, Spain
| | - Jackson LiangYao Li
- Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid 28029, Spain; Singapore Immunology Nework (SIgN), A(∗)STAR, Biopolis, Singapore 138648, Singapore
| | - Akhila Balachander
- Singapore Immunology Nework (SIgN), A(∗)STAR, Biopolis, Singapore 138648, Singapore
| | - Juan A Quintana
- Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid 28029, Spain
| | | | | | - Andrés Pun-García
- Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid 28029, Spain
| | - Paqui G Través
- Molecular Neurobiology Laboratory, the Salk Institute for Biological Studies, La Jolla, CA 92037, USA
| | - Elena Bonzón-Kulichenko
- Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid 28029, Spain; CIBER de enfermedades cardiovasculares (CIBERCV), Madrid 28029, Spain
| | | | - Lorena Cussó
- Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid 28029, Spain; Departamento de Bioingeniería e Ingeniería Aeroespacial, Universidad Carlos III de Madrid, Madrid 28911, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid 28009, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid 28029, Spain
| | - Noelia A-González
- Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid 28029, Spain; Institute of Immunology, University of Muenster, Muenster 48149, Germany
| | | | - Marta Roche-Molina
- Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid 28029, Spain
| | | | - Georgiana Crainiciuc
- Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid 28029, Spain
| | - Gabriela Guzmán
- Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid 28029, Spain; Hospital Universitario La Paz, IdIPaz, Madrid 28046, Spain
| | - Jagoba Larrazabal
- Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid 28029, Spain
| | - Elías Herrero-Galán
- Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid 28029, Spain
| | | | - Greg Lemke
- Molecular Neurobiology Laboratory, the Salk Institute for Biological Studies, La Jolla, CA 92037, USA
| | - Carla V Rothlin
- Departments of Immunobiology and Pharmacology, Yale University, New Haven, CT 06520, USA
| | - Luis Jesús Jimenez-Borreguero
- CIBER de enfermedades cardiovasculares (CIBERCV), Madrid 28029, Spain; Hospital Universitario de La Princesa, Madrid 28006, Spain
| | | | - Antonio Castrillo
- Instituto Investigaciones Biomédicas "Alberto Sols," CSIC-UAM, Madrid 28029, Spain; Unidad de Biomedicina IIBM-Universidad de las Palmas de Gran Canaria (ULPGC) (Unidad Asociada al CSIC), Las Palmas 35001, Spain; Instituto Universitario de Investigaciónes Biomédicas y Sanitarias, ULPGC, Las Palmas 35016, Spain
| | - Manuel Desco
- Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid 28029, Spain; Departamento de Bioingeniería e Ingeniería Aeroespacial, Universidad Carlos III de Madrid, Madrid 28911, Spain
| | - Pura Muñoz-Cánoves
- Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid 28029, Spain; Department of Experimental & Health Sciences, Universitat Pompeu Fabra, CIBERNED, Barcelona 08003, Spain; ICREA, Barcelona 08908, Spain
| | - Borja Ibáñez
- Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid 28029, Spain; CIBER de enfermedades cardiovasculares (CIBERCV), Madrid 28029, Spain; IIS- Fundación Jiménez Díaz Hospital, Madrid 28040, Spain
| | - Miguel Torres
- Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid 28029, Spain
| | - Lai Guan Ng
- Singapore Immunology Nework (SIgN), A(∗)STAR, Biopolis, Singapore 138648, Singapore
| | - Silvia G Priori
- Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid 28029, Spain; Molecular Cardiology, ICS-Maugeri IRCCS, Pavia 27100, Italy; Department of Molecular Medicine, University of Pavia, Pavia 2700, Italy
| | - Héctor Bueno
- Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid 28029, Spain; CIBER de enfermedades cardiovasculares (CIBERCV), Madrid 28029, Spain
| | - Jesús Vázquez
- Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid 28029, Spain; CIBER de enfermedades cardiovasculares (CIBERCV), Madrid 28029, Spain
| | - Mario D Cordero
- Oral Medicine Department, University of Sevilla, Seville 41009, Spain; Cátedra de Reproducción y Genética Humana del Instituto para el Estudio de la Biología de la Reproducción Humana (INEBIR) y la Universidad Europea del Atlántico (UNEATLANTICO), Seville 41009, Spain; Fundación Universitaria Iberoamericana (FUNIBER), Barcelona 08005, Spain
| | - Juan A Bernal
- Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid 28029, Spain
| | - José A Enríquez
- Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid 28029, Spain; CIBER de fragilidad y envejecimiento saludable (CIBERFES), Madrid 28029, Spain.
| | - Andrés Hidalgo
- Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid 28029, Spain.
| |
Collapse
|
12
|
Roche-Molina M, Hardwick B, Sanchez-Ramos C, Sanz-Rosa D, Gewert D, Cruz FM, Gonzalez-Guerra A, Andres V, Palma JA, Ibanez B, Mckenzie G, Bernal JA. The pharmaceutical solvent N-methyl-2-pyrollidone (NMP) attenuates inflammation through Krüppel-like factor 2 activation to reduce atherogenesis. Sci Rep 2020; 10:11636. [PMID: 32669659 PMCID: PMC7363918 DOI: 10.1038/s41598-020-68350-2] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2020] [Accepted: 06/19/2020] [Indexed: 12/25/2022] Open
Abstract
N-methyl-2-pyrrolidone (NMP) is a versatile water-miscible polar aprotic solvent. It is used as a drug solubilizer and penetration enhancer in human and animal, yet its bioactivity properties remain elusive. Here, we report that NMP is a bioactive anti-inflammatory compound well tolerated in vivo, that shows efficacy in reducing disease in a mouse model of atherosclerosis. Mechanistically, NMP increases the expression of the transcription factor Kruppel-like factor 2 (KLF2). Monocytes and endothelial cells treated with NMP express increased levels of KLF2, produce less pro-inflammatory cytokines and adhesion molecules. We found that NMP attenuates monocyte adhesion to endothelial cells inflamed with tumor necrosis factor alpha (TNF-α) by reducing expression of adhesion molecules. We further show using KLF2 shRNA that the inhibitory effect of NMP on endothelial inflammation and subsequent monocyte adhesion is KLF2 dependent. Enhancing KLF2 expression and activity improves endothelial function, controls multiple genes critical for inflammation, and prevents atherosclerosis. Our findings demonstrate a consistent effect of NMP upon KLF2 activation and inflammation, biological processes central to atherogenesis. Our data suggest that inclusion of bioactive solvent NMP in pharmaceutical compositions to treat inflammatory disorders might be beneficial and safe, in particular to treat diseases of the vascular system, such as atherosclerosis.
Collapse
Affiliation(s)
- Marta Roche-Molina
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Melchor Fernandez Almagro 3, CP28029, Madrid, Spain
| | - Bryn Hardwick
- MRC Cancer Unit At the University of Cambridge, Hutchison/MRC Research Centre, Box 197, Biomedical Campus, Hills Road, Cambridge, CB2 0XZ, UK
| | - Cristina Sanchez-Ramos
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Melchor Fernandez Almagro 3, CP28029, Madrid, Spain
| | - David Sanz-Rosa
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Melchor Fernandez Almagro 3, CP28029, Madrid, Spain.,CIBERCV, Madrid, Spain.,Department of Medicine, Universidad Europea de Madrid, Madrid, Spain
| | - Dirk Gewert
- DG Bioconsult Ltd, 50 Gilbert Road, Cambridge, CB4 3PE, UK
| | - Francisco M Cruz
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Melchor Fernandez Almagro 3, CP28029, Madrid, Spain
| | - Andres Gonzalez-Guerra
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Melchor Fernandez Almagro 3, CP28029, Madrid, Spain
| | - Vicente Andres
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Melchor Fernandez Almagro 3, CP28029, Madrid, Spain.,CIBERCV, Madrid, Spain
| | - Joaquin A Palma
- Department of Development, Grupo STIG, Velázquez 11, 28001, Madrid, CP, Spain
| | - Borja Ibanez
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Melchor Fernandez Almagro 3, CP28029, Madrid, Spain.,CIBERCV, Madrid, Spain.,IIS-Fundación Jiménez Díaz University Hospital, Madrid, Spain
| | - Grahame Mckenzie
- MRC Cancer Unit At the University of Cambridge, Hutchison/MRC Research Centre, Box 197, Biomedical Campus, Hills Road, Cambridge, CB2 0XZ, UK.
| | - Juan A Bernal
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Melchor Fernandez Almagro 3, CP28029, Madrid, Spain. .,CIBERCV, Madrid, Spain.
| |
Collapse
|
13
|
Oda-Kawashima K, Sedukhina AS, Okamoto N, Lytvyn M, Minagawa K, Iwata T, Kumai T, Sato E, Inada E, Yamaura A, Sakamoto M, Roche-Molina M, Bernal JA, Sato K. NF-kB signaling in cardiomyocytes is inhibited by sevoflurane and promoted by propofol. FEBS Open Bio 2020; 10:259-267. [PMID: 31898867 PMCID: PMC6996339 DOI: 10.1002/2211-5463.12783] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2019] [Revised: 12/21/2019] [Accepted: 01/02/2020] [Indexed: 11/12/2022] Open
Abstract
Both inhalational and intravenous anesthetics affect myocardial remodeling, but the precise effect of each anesthetic on molecular signaling in myocardial remodeling is unknown. Here, we performed in silico analysis to investigate signaling alterations in cardiomyocytes induced by inhalational [sevoflurane (Sevo)] and intravenous [propofol (Prop)] anesthetics. Bioinformatics analysis revealed that nuclear factor‐kappa B (NF‐kB) signaling was inhibited by Sevo and promoted by Prop. Moreover, nuclear accumulation of p65 and transcription of NF‐kB‐regulated genes were suppressed in Sevo‐administered mice, suggesting that Sevo inhibits the NF‐kB signaling pathway. Our data demonstrate that NF‐kB signaling is inhibited by Sevo and promoted by Prop. As NF‐kB signaling plays an important role in myocardial remodeling, our results suggest that anesthetics may affect myocardial remodeling through NF‐kB.
Collapse
Affiliation(s)
- Keiko Oda-Kawashima
- Department of Pharmacogenomics, St. Marianna University Graduate School of Medicine, Kawasaki, Japan.,Anesthesiology Division, Graduate School of Medicine, Juntendo University, Bunkyo-ku, Japan
| | - Anna S Sedukhina
- Department of Pharmacogenomics, St. Marianna University Graduate School of Medicine, Kawasaki, Japan
| | - Naoki Okamoto
- Department of Pharmacogenomics, St. Marianna University Graduate School of Medicine, Kawasaki, Japan
| | - Mariya Lytvyn
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain
| | - Kimino Minagawa
- Department of Pharmacogenomics, St. Marianna University Graduate School of Medicine, Kawasaki, Japan
| | - Teppei Iwata
- Department of Pharmacogenomics, St. Marianna University Graduate School of Medicine, Kawasaki, Japan
| | - Toshio Kumai
- Department of Pharmacogenomics, St. Marianna University Graduate School of Medicine, Kawasaki, Japan
| | - Eri Sato
- Department of Pharmacogenomics, St. Marianna University Graduate School of Medicine, Kawasaki, Japan
| | - Eiichi Inada
- Anesthesiology Division, Graduate School of Medicine, Juntendo University, Bunkyo-ku, Japan
| | - Ayako Yamaura
- Department of Anesthesiology, St. Marianna University School of Medicine, Kawasaki, Japan
| | - Miki Sakamoto
- Department of Anesthesiology, St. Marianna University School of Medicine, Kawasaki, Japan
| | - Marta Roche-Molina
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain
| | - Juan A Bernal
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain
| | - Ko Sato
- Department of Pharmacogenomics, St. Marianna University Graduate School of Medicine, Kawasaki, Japan
| |
Collapse
|
14
|
Roche-Molina M, Sanz-Rosa D, Cruz FM, García-Prieto J, López S, Abia R, Muriana FJ, Fuster V, Ibáñez B, Bernal JA. Induction of Sustained Hypercholesterolemia by Single Adeno-Associated Virus–Mediated Gene Transfer of Mutant hPCSK9. Arterioscler Thromb Vasc Biol 2015; 35:50-9. [DOI: 10.1161/atvbaha.114.303617] [Citation(s) in RCA: 112] [Impact Index Per Article: 12.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Affiliation(s)
- Marta Roche-Molina
- From the Cardiovascular Development and Repair Department (M.R.-M., F.M.C., J.A.B.), and Epidemiology, Atherothrombosis and Imaging Department (D.S.-R., J.G.-P., V.F., B.I.), Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain; Laboratory of Cellular and Molecular Nutrition, Instituto de la Grasa (CSIC), Seville, Spain (S.L., R.A., F.J.G.M.); The Zena and Michael a Wiener Cardiovascular Institute, Mount Sinai School of Medicine, New York, NY (V.F.); and Cardiovascular Institute
| | - David Sanz-Rosa
- From the Cardiovascular Development and Repair Department (M.R.-M., F.M.C., J.A.B.), and Epidemiology, Atherothrombosis and Imaging Department (D.S.-R., J.G.-P., V.F., B.I.), Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain; Laboratory of Cellular and Molecular Nutrition, Instituto de la Grasa (CSIC), Seville, Spain (S.L., R.A., F.J.G.M.); The Zena and Michael a Wiener Cardiovascular Institute, Mount Sinai School of Medicine, New York, NY (V.F.); and Cardiovascular Institute
| | - Francisco M. Cruz
- From the Cardiovascular Development and Repair Department (M.R.-M., F.M.C., J.A.B.), and Epidemiology, Atherothrombosis and Imaging Department (D.S.-R., J.G.-P., V.F., B.I.), Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain; Laboratory of Cellular and Molecular Nutrition, Instituto de la Grasa (CSIC), Seville, Spain (S.L., R.A., F.J.G.M.); The Zena and Michael a Wiener Cardiovascular Institute, Mount Sinai School of Medicine, New York, NY (V.F.); and Cardiovascular Institute
| | - Jaime García-Prieto
- From the Cardiovascular Development and Repair Department (M.R.-M., F.M.C., J.A.B.), and Epidemiology, Atherothrombosis and Imaging Department (D.S.-R., J.G.-P., V.F., B.I.), Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain; Laboratory of Cellular and Molecular Nutrition, Instituto de la Grasa (CSIC), Seville, Spain (S.L., R.A., F.J.G.M.); The Zena and Michael a Wiener Cardiovascular Institute, Mount Sinai School of Medicine, New York, NY (V.F.); and Cardiovascular Institute
| | - Sergio López
- From the Cardiovascular Development and Repair Department (M.R.-M., F.M.C., J.A.B.), and Epidemiology, Atherothrombosis and Imaging Department (D.S.-R., J.G.-P., V.F., B.I.), Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain; Laboratory of Cellular and Molecular Nutrition, Instituto de la Grasa (CSIC), Seville, Spain (S.L., R.A., F.J.G.M.); The Zena and Michael a Wiener Cardiovascular Institute, Mount Sinai School of Medicine, New York, NY (V.F.); and Cardiovascular Institute
| | - Rocío Abia
- From the Cardiovascular Development and Repair Department (M.R.-M., F.M.C., J.A.B.), and Epidemiology, Atherothrombosis and Imaging Department (D.S.-R., J.G.-P., V.F., B.I.), Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain; Laboratory of Cellular and Molecular Nutrition, Instituto de la Grasa (CSIC), Seville, Spain (S.L., R.A., F.J.G.M.); The Zena and Michael a Wiener Cardiovascular Institute, Mount Sinai School of Medicine, New York, NY (V.F.); and Cardiovascular Institute
| | - Francisco J.G. Muriana
- From the Cardiovascular Development and Repair Department (M.R.-M., F.M.C., J.A.B.), and Epidemiology, Atherothrombosis and Imaging Department (D.S.-R., J.G.-P., V.F., B.I.), Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain; Laboratory of Cellular and Molecular Nutrition, Instituto de la Grasa (CSIC), Seville, Spain (S.L., R.A., F.J.G.M.); The Zena and Michael a Wiener Cardiovascular Institute, Mount Sinai School of Medicine, New York, NY (V.F.); and Cardiovascular Institute
| | - Valentín Fuster
- From the Cardiovascular Development and Repair Department (M.R.-M., F.M.C., J.A.B.), and Epidemiology, Atherothrombosis and Imaging Department (D.S.-R., J.G.-P., V.F., B.I.), Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain; Laboratory of Cellular and Molecular Nutrition, Instituto de la Grasa (CSIC), Seville, Spain (S.L., R.A., F.J.G.M.); The Zena and Michael a Wiener Cardiovascular Institute, Mount Sinai School of Medicine, New York, NY (V.F.); and Cardiovascular Institute
| | - Borja Ibáñez
- From the Cardiovascular Development and Repair Department (M.R.-M., F.M.C., J.A.B.), and Epidemiology, Atherothrombosis and Imaging Department (D.S.-R., J.G.-P., V.F., B.I.), Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain; Laboratory of Cellular and Molecular Nutrition, Instituto de la Grasa (CSIC), Seville, Spain (S.L., R.A., F.J.G.M.); The Zena and Michael a Wiener Cardiovascular Institute, Mount Sinai School of Medicine, New York, NY (V.F.); and Cardiovascular Institute
| | - Juan A. Bernal
- From the Cardiovascular Development and Repair Department (M.R.-M., F.M.C., J.A.B.), and Epidemiology, Atherothrombosis and Imaging Department (D.S.-R., J.G.-P., V.F., B.I.), Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain; Laboratory of Cellular and Molecular Nutrition, Instituto de la Grasa (CSIC), Seville, Spain (S.L., R.A., F.J.G.M.); The Zena and Michael a Wiener Cardiovascular Institute, Mount Sinai School of Medicine, New York, NY (V.F.); and Cardiovascular Institute
| |
Collapse
|
15
|
Acín-Pérez R, Carrascoso I, Baixauli F, Roche-Molina M, Latorre-Pellicer A, Fernández-Silva P, Mittelbrunn M, Sanchez-Madrid F, Pérez-Martos A, Lowell CA, Manfredi G, Enríquez JA. ROS-triggered phosphorylation of complex II by Fgr kinase regulates cellular adaptation to fuel use. Cell Metab 2014; 19:1020-33. [PMID: 24856931 PMCID: PMC4274740 DOI: 10.1016/j.cmet.2014.04.015] [Citation(s) in RCA: 90] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/26/2013] [Revised: 02/13/2014] [Accepted: 04/03/2014] [Indexed: 11/27/2022]
Abstract
Electron flux in the mitochondrial electron transport chain is determined by the superassembly of mitochondrial respiratory complexes. Different superassemblies are dedicated to receive electrons derived from NADH or FADH2, allowing cells to adapt to the particular NADH/FADH2 ratio generated from available fuel sources. When several fuels are available, cells adapt to the fuel best suited to their type or functional status (e.g., quiescent versus proliferative). We show that an appropriate proportion of superassemblies can be achieved by increasing CII activity through phosphorylation of the complex II catalytic subunit FpSDH. This phosphorylation is mediated by the tyrosine-kinase Fgr, which is activated by hydrogen peroxide. Ablation of Fgr or mutation of the FpSDH target tyrosine abolishes the capacity of mitochondria to adjust metabolism upon nutrient restriction, hypoxia/reoxygenation, and T cell activation, demonstrating the physiological relevance of this adaptive response.
Collapse
Affiliation(s)
- Rebeca Acín-Pérez
- Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Melchor Fernández Almagro, 3, 28029 Madrid, Spain
| | - Isabel Carrascoso
- Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Melchor Fernández Almagro, 3, 28029 Madrid, Spain
| | - Francesc Baixauli
- Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Melchor Fernández Almagro, 3, 28029 Madrid, Spain
| | - Marta Roche-Molina
- Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Melchor Fernández Almagro, 3, 28029 Madrid, Spain
| | - Ana Latorre-Pellicer
- Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Melchor Fernández Almagro, 3, 28029 Madrid, Spain
| | - Patricio Fernández-Silva
- Departamento de Bioquímica y Biología Molecular y Celular, Facultad de Ciencias, Universidad de Zaragoza, 50009 Zaragoza, Spain
| | - María Mittelbrunn
- Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Melchor Fernández Almagro, 3, 28029 Madrid, Spain
| | - Francisco Sanchez-Madrid
- Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Melchor Fernández Almagro, 3, 28029 Madrid, Spain
| | - Acisclo Pérez-Martos
- Departamento de Bioquímica y Biología Molecular y Celular, Facultad de Ciencias, Universidad de Zaragoza, 50009 Zaragoza, Spain
| | - Clifford A Lowell
- Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA 94143, USA
| | - Giovanni Manfredi
- Brain and Mind Research Institute, Weill Medical College of Cornell University, New York, NY 10065, USA
| | - José Antonio Enríquez
- Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Melchor Fernández Almagro, 3, 28029 Madrid, Spain; Departamento de Bioquímica y Biología Molecular y Celular, Facultad de Ciencias, Universidad de Zaragoza, 50009 Zaragoza, Spain.
| |
Collapse
|
16
|
McNeill L, Salmond RJ, Cooper JC, Carret CK, Cassady-Cain RL, Roche-Molina M, Tandon P, Holmes N, Alexander DR. The differential regulation of Lck kinase phosphorylation sites by CD45 is critical for T cell receptor signaling responses. Immunity 2007; 27:425-37. [PMID: 17719247 DOI: 10.1016/j.immuni.2007.07.015] [Citation(s) in RCA: 131] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2006] [Revised: 05/20/2007] [Accepted: 07/03/2007] [Indexed: 01/27/2023]
Abstract
The molecular mechanisms whereby the CD45 tyrosine phosphatase (PTPase) regulates T cell receptor (TCR) signaling responses remain to be elucidated. To investigate this question, we have reconstituted CD45 (encoded by Ptprc)-deficient mice, which display severe defects in thymic development, with five different expression levels of transgenic CD45RO, or with mutant PTPase null or PTPase-low CD45R0. Whereas CD45 PTPase activity was absolutely required for the reconstitution of thymic development, only 3% of wild-type CD45 activity restored T cell numbers and normal cytotoxic T cell responses. Lowering the CD45 expression increased CD4 lineage commitment. Peripheral T cells with very low activity of CD45 phosphatase displayed reduced TCR signaling, whereas intermediate activity caused hyperactivation of CD4+ and CD8+ T cells. These results are explained by a rheostat mechanism whereby CD45 differentially regulates the negatively acting pTyr-505 and positively acting pTyr-394 p56(lck) tyrosine kinase phosphorylation sites. We propose that high wild-type CD45 expression is necessary to dephosphorylate p56(lck) pTyr-394, suppressing CD4 T+ cell lineage commitment and hyperactivity.
Collapse
Affiliation(s)
- Louise McNeill
- Laboratory of Lymphocyte Signalling and Development, The Babraham Institute, Babraham, Cambridge CB2 4AT, UK
| | | | | | | | | | | | | | | | | |
Collapse
|